The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, explicitly stating that the company’s new drug application for bitopertin lacked sufficient evidence for approval. The resulting market reaction wiped out significant shareholder value, prompting the New York-based firm to seek out affected investors for a potential class action lawsuit.
Rosen Law Firm Investigates Disc Medicine Over Misleading Disclosure Claims
A 22 percent drop in Disc Medicine’s stock price following a February 13, 2026, FDA rejection has triggered a formal investigation by the Rosen Law Firm. Attorneys are currently reviewing potential securities claims, alleging the company provided investors with materially misleading information regarding its bitopertin drug program.
Rosen Law Firm is currently soliciting inquiries from those who purchased Disc Medicine securities before the price decline. The firm, which operates on a contingency fee basis, is positioning itself to represent shareholders in recouping losses. Investors interested in participating in the prospective litigation are directed to contact Phillip Kim at 866-767-3653 or submit their details through the firm’s online portal. While the firm highlights its history of high-profile settlements and legal rankings, they note that prior results do not guarantee future outcomes in this specific matter.
Comments (0)
No comments yet. Be the first!